How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (review of TA761)

Closed for comments This consultation ended on at   Request commenting lead permission

2 Marketing authorisation indication

2.1

Osimertinib (Tagrisso, AstraZeneca) is indicated for 'adjuvant treatment following complete tumour resection in adults with stage IB to IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations'.

Price

2.3

The list price for osimertinib is £5,770 per 30 pack of 80‑mg tablets (NICE BNF, June 2024). The company has a commercial arrangement (simple discount patient access scheme). This makes osimertinib available to the NHS with a discount. The size of the discount is commercial in confidence.